| Background:Hepatitis B virus is the main cause of human acute liver disease and chronic infections pathogens. Around the world has a population of 350 million are now a chronic hepatitis B infection, for good hair of liver failure, liver cirrhosis and liver cancer. Current clinical treatment, include interferon alpha and nucleotide drugs, treatment for hepatitis B virus effect is limited, main reason is unable to eradicate the viral DNA template. After treatment of common problems are drug-resistant strains selected, and the high rate of relapse after drug withdrawal. Therefore, development of new treatments is the main challenge of the medical profession. The disease in our country and the world widely popular, a variety of transmitted between people, the high incidence and harmfulness is large, the world’s first of all kinds of infectious diseases, is one of the difficult disease of the human need to overcome. Chronic hepatitis b was almost worldwide distribution, and chronic hepatitis b infection of about 300 million people around the world. It is according to epidemiological survey in 2006 in China: at present our country has chronic asymptomatic carriers of hepatitis b virus (HBV), and it is about 120 million people in the hepatitis b for 12 million people, the annual incidence of 120/10. Such as higher lamivudine resistance as the example, application 1～5 years the incidence of drug resistance were 14%,38%, 49%,67%,69%. Such as lower adefovir resistance ester, for example, the prevalence of drug resistance in HBeAg positive chronic hepatitis b (1-5 years respectively 0, 3%,11%,18%,11%, HBeAg negative 1,2,3 years the incidence of drug resistance of 0,3%,5.9%-11%respectively, at the same time, the drug has a certain kidney toxicity. Entecavir in patients with early cure drug resistance rate of O 1 year,3 years of accumulated resistance rate is only 1.2%, and no obvious side effects, so is ideal anti-viral drugs in clinic.Research purposes:According to the clinical blood stasis syndrome of chronic hepatitis B viral hepatitis to change common characteristics, is establishment of liver, spleen, blood for treatment. Through the observation with liver spleen and blood cubic of nine liver capsules in the treatment of chronic hepatitis B patients with viral hepatitis clinical research, to evaluate the effect of this medicine and safety, improve the clinical effect of TCM treatment of chronic hepatitis B viral hepatitis. Clinical research further explores the mechanism of the formulas for large-scale popularization and application. At the same time can lay the foundation for follow-up study. This section from the perspective of data and statistical analysis, the preliminary exploration liver spleen, promoting blood circulation to remove blood stasis method, mechanism of intervention effect on chronic hepatitis b.Research methods:All medical records are from January 2013-June 2014 subsidiary in Kunshan Jiangsu university hospital for infectious diseases department in hospital and clinic diagnosis of chronic hepatitis B patients,40 cases were randomly divided into treatment group and control group 40 cases. Both groups of oral entecavir,0.5 mg each time,1,1 times. Group (treatment group) on the basis of oral entecavir, at the same time take nine proprietary Chinese medicine taste for liver capsule,3 times a day, each time four grain of oral. Control group only oral entecavir treatment, not taking nine tastes for liver capsule and other liver enzymes, regulating the immunity, resisting hepatic fibrosis drug. For patients with chronic hepatitis B type long-acting interferon treatment still lacks practical biological indicators to predict the curative effect.Results:From the clinical study part, according to the results of treatment group cure rate and efficiency are 42.5% and 42.5% respectively, the total effective rate was 92.5%; Control group cure rate and efficiency are 27.5% and 27.5% respectively, the total effective rate was 75%. The total effective rate in treatment group compared with control group, the difference was statistically significant, P< 0.05). We can be concluded that the treatment group curative effect is better than the control group. When comparing the symptoms integral, results showed that the experimental groups all have different degrees of improvement, compared with before treatment, the difference was statistically significant (P< 0.01); Nearly a century of power, in appetence, also to have certain to improve, but no significant difference (P> 0.05). Suggest that nine tastes for liver capsule can obviously improve the patient’s pain, poor appetite symptoms, compared with control group; the difference was statistically significant (P< 0.05). This study compared two groups of liver function before and after treatment, two groups of ALT, AST, ALP, GGT, TBiL have improvement action, at the same time in the two groups after treatment of ALT, AST, the difference was statistically significant (p< 0.05). The treatment group of liver function decline is more apparent. In observing two groups of HBeAg seroconversion and virology indexes, the treatment group compared with control group, HBeAg Yin turn and HBV-DNA Yin turn differences had no statistical significance. Two groups of patients with elevated serum HA, LN, type IV collagen has a different degree of lower, before the treatment have.significant differences (P< 0.05). Visible in the two groups had similar effects on liver fibrosis. In entecavir tablet on the premise of foundation treatment, two groups of inflammation of the liver have good inhibitory effect.40 cases of patients were measured serum levels of CD3, CD4, CD8 and CD4/CD8 ratio, including 20 cases in treatment group and control group 20 cases. CD4 cells increased after the treatment, CD8 cells to fall, the difference was statistically significant, showed that nine tastes for liver capsule has good immunity effect..Conclusion:Jiuweigantan capsule can improve chronic hepatitis B patients with viral hepatitis change the blood stasis symptoms, signs, improve the patient’s liver function, reduce liver cell inflammation, protect the liver cells. |
PDF Full Text Request